S. 3466 · 114th Congress
Accelerating New Pharmaceutical Competition Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 114th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
PaulSponsorNo cosponsors.
This bill amends the Federal Food, Drug, and Cosmetic Act to permit brand name drug applications to rely upon investigations conducted in certain foreign countries if the drug has been approved in the foreign country where the investigations were conducted. The Food and Drug Administration (FDA) has 90 days to act on these applications.
What it does: CRS summary · Introduced in Senate · Sep 29, 2016
Accelerating New Pharmaceutical Competition Act
This bill amends the Federal Food, Drug, and Cosmetic Act to permit brand name drug applications to rely upon investigations conducted in certain foreign countries if the drug has been approved in the foreign country where the investigations were conducted. The Food and Drug Administration (FDA) has 90 days to act on these applications.
The bill revises a provision regarding the effective date of the approval of a generic drug that is subject to a patent infringement action.
The FDA must prioritize the review of, and act within 150 days on, generic drug applications or supplements to generic drug applications for drugs: (1) for which there is a shortage, or (2) that have not been recently introduced to the market by more than one manufacturer and for which tentative approval has not been granted to more than two applications.Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Accelerating New Pharmaceutical Competition Act
Latest action (Sep 29, 2016): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Policy area: Health · Origin: Senate · Introduced: Sep 29, 2016
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.